Dr. Ebot Eyong is a Sr. Principal Regulatory Affairs Consultant for advanced MedTech, BioTech, and pharmaceutical development. A motivated and result-oriented Biomedical Engineer and Regulatory Affairs Leader with an extensive background in new product development with 15+ years of experience in Quality Engineering, Quality Assurance, Quality Systems Implementation, Global Regulatory Strategy, Regulatory Compliance, and Regulatory Submissions(510K, PMA, IDE, EUMDR/IVDR, CTAs, IND, NDA, BLA, eCTD 4.0, etc.), with 10+ years of management experience in projects relating to new medical devices/Drugs/IVDs/ Combination devices. As a principal consultant for E&E Medicals and consulting, he has dedicated his career to working with global MedTech, BioTech, pharmaceutical companies, and regulatory agencies with an exceptional record of gaining regulatory approvals and clearances for new products in existing and emerging markets (AMERS, APAC, LATAM, EMEA, ASEAN, META). He serves as Final Reviewer for Recognized FDA 510K Third Party Review Organizations. He has also managed remediation activities involving observations/warning letters/recall actions, providing project management skills, including cross-functional communication, and delegation of responsibilities across stakeholders. His Lean Six Sigma (Master Black Belt) experience facilitates executing streamlined deliverables at competitive levels. Dr. Eyong earned his doctorate in Engineering Management from Walden University. Dr. Eyong is entertaining opportunities to discuss his newest book (MED – CHAINS & COVID-19: Innovative Solutions for Pandemics). His thoroughly researched approach to pandemics employs the expertise of respected medical researchers, acclaimed scientists, and innovative medical device and drug developers across the industry.
Dr. Ebot Eyong is a Sr. Principal Regulatory Affairs Consultant for advanced MedTech, BioTech, and pharmaceutical development. A motivated and result-oriented Biomedical Engineer and Regulatory Affairs Leader with an extensive background in new product development with 15+ years of experience in Quality Engineering, Quality Assurance, Quality Systems Implementation, Global Regulatory Strategy, Regulatory Compliance, and Regulatory Submissions(510K, PMA, IDE, EUMDR/IVDR, CTAs, IND, NDA, BLA, eCTD 4.0, etc.), with 10+ years of management experience in projects relating to new medical devices/Drugs/IVDs/ Combination devices. As a principal consultant for E&E Medicals and consulting, he has dedicated his career to working with global MedTech, BioTech, and regulatory agencies with an exceptional record of gaining regulatory approvals and clearances for new products in existing and emerging markets (AMERS, APAC, LATAM, EMEA, ASEAN, META). He serves as Final Reviewer for Recognized FDA 510K Third Party Review Organizations. He has also managed remediation activities involving observations/warning letters/recall actions, providing project management skills, including cross-functional communication, and delegation of responsibilities across stakeholders. His Lean Six Sigma (Master Black Belt) experience facilitates executing streamlined deliverables at competitive levels. Dr. Eyong earned his doctorate in Engineering Management from Walden University. Dr. Eyong is entertaining opportunities to discuss his newest book (MED – CHAINS & COVID-19: Innovative Solutions for Pandemics). His thoroughly researched approach to pandemics employs the expertise of respected medical researchers, acclaimed scientists, and innovative medical device and drug developers across the industry.
MED-CHAINS – “A Groundbreaking Exploration of Pandemics”
Med-Chains is about the interrelations and challenges faced by countries in finding solutions during pandemics. The effects of disruptions within the healthcare system and the activities that lead to shortages in medical supplies, regulatory challenges, government interventions, re-engineering, and geo-economic consequences during a pandemic are relatively connected.
This publication will feature opinions from leaders of the healthcare industry, across the public and private sphere, including Presidents, Government Ministers, IHOs, CEOs, Scientists, and independent minds across Med-Chains. It includes, resources, opinion pieces, and essential data needed in solving pandemics.
The book is published in ten languages – English, French, Spanish, German, Portuguese, Chinese, Russian, Arabic, Latin, Japanese
Now Available At These Retailers
Now Available in Ebook, paperback, and audiobook
What do stress and the coronavirus have in common?
The COVID-19 pandemic changed the way we work fundamentally. Suddenly we had to take an invisible enemy into account and respect several precautions to minimize
This book will be available in ten languages: English, French, Spanish, German, Portuguese, Chinese, Russian, Arabic, Latin, and Japanese. Let us start the conversation……
“All proceeds from the book will go to charities that help kids who lost a parent during this pandemic.”